ClinicalTrials.gg
Not yet recruitingNCT07157891PRGFSECKOAUpdated Sep 5, 2025

Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis

An Early Phase 1 interventional study of MSC-Derived Secretome and MSC-Derived Secretome + Autologous PRGF in Osteoarthritis (OA), Knee Injury and Cartilage Degeneration, sponsored by University of the Punjab. Not yet recruiting. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's title name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of the Punjab · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
30 Years to 55 Years
Sex
All
01

Study summary

This Phase I/II randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.

Read the detailed description

Osteoarthritis (OA) is a chronic, degenerative joint disease characterized by progressive cartilage degradation, joint space narrowing, subchondral bone remodeling, inflammation, and pain that ultimately impair mobility and quality of life. Current treatment options, including analgesics, corticosteroids, and surgery, offer symptomatic relief but do not halt disease progression or restore joint tissue integrity.

Recent advancements in regenerative medicine have highlighted the therapeutic potential of mesenchymal stem cells (MSCs), particularly adipose-derived MSCs (AD-MSCs) and umbilical cord- derived MSCs (UC-MSCs), due to their robust paracrine activity. Rather than relying solely on cell engraftment, MSCs exert their therapeutic effects primarily through their secretome. These are complex mixtures of cytokines, growth factors, extracellular vesicles (EVs), and exosomes. This secretome can promote cartilage repair, reduce inflammation, and modulate immune responses, all without the risks associated with live cell transplantation.

This prospective, interventional study aims to evaluate the safety, tolerability, and early efficacy of intra-articular administration of MSC-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with mild to moderate symptomatic knee osteoarthritis (Kellgren-Lawrence grade II-III).The secretome will be collected from culture of human ADMSCs and UCMSCs grown in GMP-compliant labs, characterized for sterility, protein content, particle size, and bioactivity prior to administration.

Primary outcomes will include pain reduction assessment and any adverse events via Visual Analog Scale (VAS) and WOMAC index. If there will be adverse events, they will also be checked. Secondary outcomes will include functional improvement, cartilage regeneration (X-ray or MRI assessment), and changes in synovial inflammatory biomarkers (e.g., IL-1β, TNF-α, IL-6, MMP-13).

This study hypothesizes that the cell-free combination of MSC secretome and PRGF will offer regenerative benefits in knee OA, potentially improving joint function and structure while minimizing the risks associated with live cell therapies. Findings from this trial will inform the design of future large-scale studies and support the development of secretome-based regenerative therapies for osteoarthritis.

02

Conditions studied

  • Osteoarthritis (OA)
  • Knee Injury
  • Cartilage Degeneration

Browse trials for

Keywords

  • Mesenchymal Stem Cell Secretome
  • Plasma Rich in Growth Factors (PRGF)
  • Platelet-Rich Plasma (PRP)
  • Knee Osteoarthritis
  • Intra-articular Injection
  • Cell-free Therapy
  • Regenerative Medicine
03

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 25 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

University of the Punjab is the lead sponsor of 20 studies on the registry; 8 are open to participants now.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Following is the inclusion criteria for the enrolment of patients affected with damaged cartilage in this study:

    • Diagnosed with primary OA in one or both knees based on American College of Rheumatology criteria
    • Grade I and II Arthritis
    • Joint pain ≥ 20mm measured by visual analogue scale
    • Age ranges from 30-55 years of age
    • 27.12 ± 4.38
    • Patients with no previous surgical interventions to lower limb
    • Willing to participate in the study

Exclusion criteria

Exclusion Criteria:

    • Secondary OA due to trauma, infection, rheumatoid arthritis, congenital disease or other inflammatory disorders of the knee

      • Diagnosed with a systemic disorder, immunodeficiency or coagulation disorder
      • Had history of
      • History of allergy or allergic constitution
      • Pregnant or breastfeeding women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    MSC-Derived Secretome

    MSC-derived secretome will be administered as intra-articular injections under ultrasound guidance to the affected knee. Injection will be given twice, each after 6 months. Each injection will consist of 2 mL of concentrated MSC-derived secretome.

    Biological: MSC-Derived Secretome

  • Experimental
    MSC-Derived Secretome + Autologous PRGF

    MSC-derived secretome combined with autologous plasma-rich in growth factors plasma (PRGF) will be administered as intra-articular injections under ultrasound guidance to the affected knee. Injections will be given twice, each after 6 months. Each injection will consist of 2 mL of concentrated MSC-derived secretome and 1 mL of autologous PRGF, totaling 3 mL per dose.

    Biological: MSC-Derived Secretome + Autologous PRGF

Interventions

  • BiologicalMSC-Derived Secretome

    The secretome will be collected from cultured MSCs under sterile, GMP-compliant conditions and concentrated to retain bioactive molecules. It will be injected into the affected knee under ultrasound guidance.

    Also known as: Conditioned Medium, MSC Secretome Therapy

  • BiologicalMSC-Derived Secretome + Autologous PRGF

    MSC-derived secretome will be collected from mesenchymal stem cell cultures under sterile, GMP-compliant conditions. Autologous PRP will be prepared from the participant's own peripheral blood using a standardized single-spin centrifugation method and combined with 10% calcium chloride to activate growth factors. Both components will be mixed and administered into the affected joint under ultrasound guidance.

    Also known as: MSC-Secretome/PRGF Combined Therapy

06

What researchers measure

Primary outcomes

  1. Change in Knee Pain (VAS Score) Change in WOMAC Score Adverse Events (Safety Monitoring)

    Participants are evaluated for change in pain intensity using the Visual Analog Scale (VAS). Best outcome: pain score significantly reduced. If any Worst outcome: no change or increased pain. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) will be used to assess pain, stiffness, and physical function. Best outcome: improved total WOMAC score. Any local or systemic adverse events related to intra-articular administration of MSC secretome + PRP will be monitored and documented. Events will be categorized by type, severity, and relation to treatment.

    Time frame: From enrollment through the treatment period (Day 0 to Day 14); and at follow-up visits at 1 month, 3 months, 6 months, and 12 months post-treatment.

Other outcomes

  1. Change in Cartilage Thickness (MRI) Synovial Fluid Biomarkers Patient Global Assessment

    Evaluation of articular cartilage thickness, signal intensity, and subchondral bone integrity using MRI. Best outcome: increased or preserved cartilage thickness, reduced signal abnormalities. Quantification of inflammatory biomarkers (e.g., IL-1β, TNF-α, MMP-13) in synovial fluid to assess joint inflammation. Best outcome: significant reduction in pro-inflammatory marker levels post-treatment. Self-reported patient evaluation of symptom relief and joint mobility using a standardized global assessment scale. Best outcome: improved self-perceived joint health.

    Time frame: From enrollment through the treatment period (Day 0 to Day 14); and at follow-up visits at 1 month, 3 months, 6 months, and 12 months post-treatment.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2027, 24 months later.

Of 61 phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Dec 11, 2027
CompletionEst.
Dec 11, 2028
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07157891
Lead sponsor
University of the Punjab
Collaborators
Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.
Responsible party
Noreen Latief (Assistant Professor, University of the Punjab) — Principal investigator
First posted
Sep 5, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Dec 11, 2027 (estimated)
Completion
Dec 11, 2028 (estimated)
Last update
Sep 5, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion